RELMADA THERAPEUTICS INC
RLMDNASDAQ🏆 #2423 by market capUS Equity
$678.47▼ $47.90 (−7.06%)
Simulated price1h—
24h▼ 7.1%
7d—
14d—
30d—
1y—
🏦Market Cap
$477M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
43
Weak
No chart data available for RLMD.
Trading Snapshot
- Day Range
- $670.59 – $688.14
- 52-Week Range
- $0.55 – $8.00
- Volume
- $2.95B
- Avg Volume
- $3.35B
- Shares Outstanding
- 104.9M
- Next Earnings
- Oct 18, 2026
Fundamentals Snapshot
- Annual Revenue
- $47M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.15
- Dividend Yield
- —
Why Investors Own RLMD
- ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 41% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$47M▲ +25.8% YoY
Gross Margin (TTM)
41.0%▲ +0.4% YoY
Operating Income (TTM)
$9M▲ +25.8% YoY
Free Cash Flow (TTM)
$8M▲ +25.8% YoY
About RELMADA THERAPEUTICS INC
A company profile for RELMADA THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
43/100
Analyst Price Target
ⓘAverage Target
$840.20
▲ +23.8% Upside
High Target$931.82
Low Target$679.08
Based on 39 analysts
Latest News & Updates
🚀
Reuters·2h ago
RELMADA THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift RLMD price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
RELMADA THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.